Portfolio News
- May 14, 2013 AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
- May 13, 2013 Mirna Therapeutics is First to Advance MicroRNA into the Clinic for Cancer
- May 02, 2013 Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA
- May 02, 2013 Hyperion Therapeutics Exercises Option to Acquire Rights to Buphenyl® and Ammonul®
- April 17, 2013 - BioWorld TodayAuris Medical Gets $51M For Hearing Disorder Drugs
- April 16, 2013 Auris Medical secures CHF 47.1 mn Series C financing from Sofinnova Ventures and Sofinnova Partners to advance ground-breaking inner ear therapies through Phase III clinical development
- April 08, 2013 Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R)
- March 25, 2013 SARcode Bioscience Announces Acquisition by Shire US Holdings Inc.
- March 25, 2013 - BioCenturyLabrys: Navigating migraine
- March 08, 2013 Hyperion Therapeutics Announces Pricing of Follow-On Offering
- March 05, 2013 TESARO Announces Closing of Public Offering and Full Exercise of Over-Allotment Option by Underwriters
- February 26, 2013 Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia
- February 25, 2013 Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI
- February 04, 2013 - BioWorld TodayBulls Proved Right: Hyperion's Ravicti Wins Approval in UCD
- January 31, 2013 KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering